来自 Maksym Misichenko · Nasdaq ·
AI智能体对这条新闻的看法
Despite strong fundamentals like 75% recurring revenue and 17% procedure growth, the panel is cautious due to high valuation (51x forward P/E), potential slowdown in procedure volumes, rising competition, and the risk of margin compression from new robotic platforms.
风险: High valuation and potential slowdown in procedure volumes or margin compression due to competition.
机会: None explicitly stated.
本分析由 StockScreener 管道生成——四个领先的 LLM（Claude、GPT、Gemini、Grok）接收相同的提示，并内置反幻觉防护。 阅读方法论 →
Intuitive Surgical 是机器人手术领域的领导者。
该公司 da Vinci 系统的销售情况良好，患者需求依然强劲。
从历史来看，2026 年的大幅股价下跌并不罕见。
Intuitive Surgical (纳斯达克：ISRG) 是一种非常特殊的股票。它不支付股息，因此收入投资者不会欣赏今天的投资机会。它也不便宜，因此价值投资者也不会喜欢它。它是一支成长型股票，最适合那些具有更具侵略性的投资者。
今天，机会在于 Intuitive Surgical 自 2026 年初以来股价下跌了大约 30%。以下是为什么这次下跌可能成为这支头 phiếu机器人手术股票的一个罕见买入机会的原因。
人工智能会创造世界上第一个万亿富翁吗？ 我们的团队刚刚发布了一份报告，内容是关于一家鲜为人知，被称为“不可或缺的垄断”的公司，它提供英伟达和英特尔都需要的关键技术。继续 »
Intuitive Surgical 生产 da Vinci 手术机器人系统。到 2026 年第一季度末，全球已安装 11,395 个系统，比上一季度增长了 12%。简而言之，尽管股价下跌，但这家医疗器械制造商的产品销售情况良好。
然而，还有一个值得考虑的第二个指标。使用 da Vinci 系统的手术数量同比增长了 17%。这意味着越来越多的手术正在使用 da Vinci 机器人进行。因此，患者需求也很强劲。
这些趋势将在每个季度波动。然而，大局非常清楚。Intuitive Surgical 的业务基础稳固。这就是为什么投资者愿意为这支股票支付溢价的原因。其市盈率高达 51 倍，这是一个只会吸引更具侵略性的成长型投资者才会感兴趣的数字。但是，市盈率远低于其五年平均水平 70 倍。
有趣的是，Intuitive Surgical 的收入只有大约 25% 来自 da Vinci 系统销售。其余的收入来自相当于零件（器械和配件）和服务。这是业务的飞轮，鉴于对机器人手术的需求，它是一种类似年金的收入来源。随着每个新的 da Vinci 安装，这个收入来源变得更具吸引力。这不仅仅是一项稳固的业务；这是一项强大的业务。并且 da Vinci 系统不断发展，获得越来越多的手术类型的监管批准。这为长期增长提供了另一个途径。
然而，股价在很短的时间内下跌了 30%。成长型投资者需要退一步，将这种下跌放在适当的背景下。正如下面的图表所示，这家医疗保健公司的股价自首次公开募股以来至少下跌了 30% 八次。每次下跌后都恢复了，并创下了新高。虽然无法确定这次是否会发生同样的情况，而且有些下跌幅度超过了 30%，但如果历史是参考的话，这次下跌将是暂时的。
在 Intuitive Surgical 的股价看似自由落体的时机介入将不容易。这需要对业务的基本实力有极大的信心。但是，新系统的销售仍然强劲，零件和服务的收入由患者对机器人手术的持续强劲需求推动。即使新的 da Vinci 系统销售放缓，该公司仍然可以通过其庞大的安装基础产生大量收入。
Intuitive Surgical 的业务不太可能一落千丈，这意味着这次下跌可能是该股票长期上涨趋势中的另一个暂时性波动。这种下跌已经发生过，但并非每天都会发生。这就是为什么更具侵略性的成长型投资者可能希望利用这似乎是这支头 phiếu机器人手术股票的一个罕见买入机会。
在您购买 Intuitive Surgical 的股票之前，请考虑以下几点：
Motley Fool Stock Advisor 分析师团队刚刚确定他们认为投资者现在应该购买的 10 支最佳股票……而 Intuitive Surgical 并没有在其中。这些股票可能会在未来几年产生巨大的回报。
考虑一下 Netflix 在 2004 年 12 月 17 日被列入此名单时……如果您当时投资了 1,000 美元，您将拥有 463,900 美元！ 或当 Nvidia 在 2005 年 4 月 15 日被列入此名单时……如果您当时投资了 1,000 美元，您将拥有 1,294,401 美元！
值得注意的是，Stock Advisor 的总平均回报率为 978%——与标准普尔 500 指数相比，市场表现优于 211%。不要错过最新的前 10 名名单，该名单可使用 Stock Advisor，并加入由个人投资者为个人投资者构建的投资社区。
**Stock Advisor 的回报率截至 2026 年 5 月 31 日。 *
Reuben Gregg Brewer 没有持有任何提到的股票。The Motley Fool 持有并推荐 Intuitive Surgical。The Motley Fool 还建议以下选项：长期购买 2028 年 1 月 520 美元看涨期权和短期卖出 2028 年 1 月 530 美元看跌期权。The Motley Fool 有一份披露政策。
本文中的观点和意见是作者的观点和意见，不一定代表纳斯达克公司的观点。
四大领先AI模型讨论这篇文章
"ISRG's premium valuation leaves scant margin of safety if utilization growth moderates from 17%."
The article correctly flags ISRG's durable flywheel—only 25% of revenue from system sales, with instruments and services providing annuity-like growth tied to an 11,395-unit installed base. Yet it underplays the 51x P/E against still-elevated growth expectations; any slowdown in procedure volumes below the recent 17% rate would compress multiples quickly. Historical 30% drawdowns have recovered, but those occurred in lower-valuation regimes. Current macro pressure on elective procedures and rising competition from newer robotic platforms are omitted risks that could extend the 2026 decline.
If procedure growth holds above 15% and new system placements accelerate, the 51x multiple could re-rate higher rather than contract, validating the dip as temporary.
"ISRG's business durability is real, but the article provides no evidence that the 30% decline was unjustified rather than a necessary multiple compression on a previously overvalued growth stock."
ISRG's 30% drawdown is real, but the article conflates historical resilience with inevitable recovery. Yes, 75% of revenue is recurring (instruments/services on 11,395 installed systems), and procedure volume grew 17% YoY—strong fundamentals. But at 51x forward P/E, we're pricing in flawless execution. The article never asks: *why* did the stock fall 30% if nothing changed? Either the market repriced growth expectations downward (suggesting prior overvaluation), or there's deteriorating guidance the article omits. A 51x multiple requires 20%+ sustained EPS growth; any slowdown in procedure adoption or margin compression becomes catastrophic. Historical 30% drawdowns recovered, but that's survivorship bias—not every stock recovers.
If the market repriced ISRG from 70x to 51x P/E on fundamentals that remain 'sound,' that's rational de-risking, not panic. The article assumes the stock *must* recover because it has before, ignoring that competitive pressure (Stryker, Medtronic advancing robotics) or regulatory headwinds could be structural, not cyclical.
"ISRG's premium valuation is only justified if they maintain their monopoly-like pricing power on recurring revenue amidst intensifying competition from Medtronic and J&J."
Intuitive Surgical (ISRG) remains a high-quality compounder, but the 51x forward P/E is a dangerous anchor in a high-rate environment. While the recurring revenue from instruments and services (75% of total) provides a defensive moat, the article ignores the rising competitive threat from Medtronic’s Hugo and Johnson & Johnson’s Ottava platforms. If these competitors gain meaningful traction, ISRG’s pricing power on replacement parts—the engine of their margin expansion—could face margin compression. A 30% drawdown is historically 'normal' for ISRG, but relying on historical volatility patterns ignores the current shift toward cheaper, open-architecture robotic alternatives that could disrupt their long-term dominance.
The 'annuity' model of instrument sales is so sticky that switching costs effectively lock hospitals into the da Vinci ecosystem for the next decade, rendering competitor entry a long-term threat rather than a near-term margin risk.
"High valuation plus capex sensitivity and potential regulatory/reimbursement headwinds risk near-term multiple compression even as the installed base grows."
Intuitive Surgical's 30% 2026 drawdown with 17% YoY procedure growth and a growing installed base looks appealing, but several risks are glossed over. The stock sits at roughly 51x earnings, leaving little cushion if growth slows or if hospitals throttle capex. Revenue is highly reliant on instruments, services, and maintenance tied to existing systems; a slowdown in new da Vinci installations or pricing pressure could erode the flywheel. Additional tailwinds like regulatory approvals or AI-driven surgical improvements may take longer than investors expect, and reimbursement dynamics or competitive threats could drive multiple contraction despite a robust installed base.
Counterpoint: the move may reflect genuine demand fatigue rather than a buy opportunity; if ISRG can't sustain installation growth or convert instrument revenue into outsized earnings, the rebound could stall.
"The multiple contraction reflects higher discount rates, not changing fundamentals, leaving further downside if yields remain elevated."
Claude's framing treats the drop from 70x to 51x P/E as evidence of either prior overvaluation or omitted deterioration. That overlooks the mechanical re-rating all high-duration growth names experienced once the 10-year yield stabilized above 4%. The same rate backdrop Gemini flagged makes sustained 20%+ EPS growth less valuable to investors today than in 2020-21, independent of ISRG's procedure trends or competitive threats.
"Rate-driven multiple compression explains valuation, not stock price decline—ISRG's 30% drop likely signals omitted operational headwinds, not just duration repricing."
Grok's rate-driven re-rating thesis is mechanically sound, but it conflates *valuation compression* with *fundamental resilience*. A 51x multiple in a 4%+ yield environment is rational—agreed. But that doesn't address Claude's core question: *why* did ISRG fall 30% if procedure growth stayed at 17%? Rate moves explain multiple contraction, not absolute drawdowns. If the stock repriced purely on duration, it should track the Nasdaq-100; instead, ISRG underperformed peers, suggesting procedure or margin deterioration the article never discloses.
"The recent drawdown reflects the deliberate, margin-dilutive cost of the da Vinci 5 product transition rather than a decline in fundamental demand."
Claude, your focus on the 30% drawdown misses the elephant in the room: the transition to the da Vinci 5 platform. ISRG is currently absorbing significant R&D and manufacturing ramp-up costs for this new system. This cycle is inherently margin-dilutive in the short term, which the market is punishing. It isn't 'deteriorating guidance' or 'hidden risks'—it is the deliberate, capital-intensive cost of maintaining the moat against Medtronic and J&J. The drawdown is a structural investment, not a fundamental failure.
"Upgrade conversion rate of da Vinci 5 within 2-3 years is the critical unknown; a slow ramp could deepen margin pressure beyond 2026."
Responding to Gemini: you frame the da Vinci 5 as a near-term margin drag; the real risk is timing, not inevitability. If upgrade uptake lags, the annuity from instruments/services may fail to offset R&D/mfg costs, pressuring margins and 2026 outlook. Open-architecture entrants could erode replacement-part pricing more than you imply. The critical unknown is upgrade conversion rate within 2-3 years; a slow ramp could be a deeper bear case than a temporary drag.
Despite strong fundamentals like 75% recurring revenue and 17% procedure growth, the panel is cautious due to high valuation (51x forward P/E), potential slowdown in procedure volumes, rising competition, and the risk of margin compression from new robotic platforms.
None explicitly stated.
High valuation and potential slowdown in procedure volumes or margin compression due to competition.